Telatinib: Final Phase II data

Final data from the open-label, U.S. and Spanish Phase II TEL0805 trial in 39 patients showed that first-line treatment with twice-daily oral telatinib plus capecitabine and cisplatin led to an ORR of 67%, including 1 complete response and 25 partial responses, plus 10 cases of stable disease. Median PFS was 140 days and median OS has not yet been reached. Data were presented at the American Society of Clinical Oncology meeting in Chicago. ...